Analysts Set AC Immune (NASDAQ:ACIU) Price Target at $7.50

AC Immune (NASDAQ:ACIU) has earned an average recommendation of “Hold” from the five analysts that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $7.50.

A number of equities analysts have recently commented on the company. BTIG Research reaffirmed a “buy” rating and issued a $8.00 price target on shares of AC Immune in a report on Monday, May 4th. Weiss Ratings cut AC Immune from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 8th. HC Wainwright restated a “buy” rating on shares of AC Immune in a research note on Wednesday, July 1st. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $7.00 price target on shares of AC Immune in a research report on Friday, March 13th.

Insider Buying and Selling

In related news, CEO Andrea Pfeifer sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $2.79, for a total transaction of $27,900.00. Following the completion of the transaction, the chief executive officer owned 3,820,288 shares of the company’s stock, valued at approximately $10,658,603.52. The trade was a 0.26% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 4.60% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in ACIU. EFG International AG purchased a new stake in shares of AC Immune in the fourth quarter worth $41,000. Private Advisor Group LLC bought a new position in AC Immune in the 3rd quarter worth about $48,000. Goldman Sachs Group Inc. increased its stake in AC Immune by 46.9% in the 4th quarter. Goldman Sachs Group Inc. now owns 18,555 shares of the company’s stock worth $58,000 after acquiring an additional 5,920 shares during the last quarter. Susquehanna International Group LLP purchased a new stake in shares of AC Immune in the 3rd quarter valued at about $63,000. Finally, Sei Investments Co. purchased a new stake in shares of AC Immune in the 2nd quarter valued at about $51,000. 51.36% of the stock is currently owned by hedge funds and other institutional investors.

AC Immune Stock Performance

NASDAQ ACIU opened at $2.54 on Wednesday. The company’s 50 day moving average is $2.62 and its 200-day moving average is $2.93. AC Immune has a 12-month low of $1.97 and a 12-month high of $4.00. The company has a quick ratio of 1.02, a current ratio of 0.87 and a debt-to-equity ratio of 0.11. The firm has a market cap of $258.50 million, a P/E ratio of -3.10 and a beta of 1.57.

AC Immune (NASDAQ:ACIU) last released its quarterly earnings data on Thursday, April 30th. The company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.01. AC Immune had a negative net margin of 1,788.02% and a negative return on equity of 125.26%. The company had revenue of $1.40 million during the quarter, compared to the consensus estimate of $0.33 million. Sell-side analysts predict that AC Immune will post -0.84 earnings per share for the current year.

AC Immune Company Profile

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.